MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacep.2025.09.029

Медицинская библиотека · JACC. Clinical electrophysiology · 2025

Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis.

Tan Min Choon, Vignarajah Aravinthan, Teo Yong Shen, Vigneswaramoorthy Nishanthi, DeSimone Christopher V, Deshmukh Abhishek J, Sorajja Dan, Lee Justin Z

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Atrial fibrillation (AF) is a common arrhythmia among patients with cardiac amyloidosis. Whereas the success rate of catheter ablation for AF may be lower due to amyloid deposition, the optimal approach to achieving rhythm control in these patients remains controversial.

OBJECTIVES

This study aims to assess the 3-year outcomes of catheter ablation for AF vs antiarrhythmic drug (AAD) therapy among patients with AF and cardiac amyloidosis using a multinational data set.

METHODS

Using the TriNetX Analytics Research Network, we included patients aged ≥18 years with a diagnosis of AF and amyloidosis between January 1, 2013, and January 1, 2021. Patients were further categorized into 2 groups: those who underwent catheter ablation for AF and those who were initiated on class I or III AAD. Patients with prior catheter ablation or class I /III AAD were excluded. The study outcomes included all-cause mortality and cardiac adverse events during a 3-year study period.

RESULTS

A total of 120 patients in the AF catheter ablation group and 4,749 in the AAD group were identified. After propensity score matching, 118 patients in each group were analyzed. Catheter ablation for AF in cardiac amyloidosis was associated with significantly lower risks of 3-year all-cause mortality (OR: 0.404; 95% CI: 0.182-0.896) and all-cause hospitalization (OR: 0.547; 95% CI: 0.317-0.942). However, no significant differences were observed in the risks of cerebrovascular attack (OR: 1; 95% CI: 0.400-2.500), cardiac arrest (OR: 1; 95% CI: 0.400-2.500), and acute heart failure (OR: 0.688; 95% CI: 0.293-1.617) between the 2 groups.

CONCLUSIONS

Catheter ablation for AF in patients with cardiac amyloidosis is associated with improved outcomes in all-cause mortality and hospitalization compared to AAD therapy. Further large-scale studies are needed to validate these potential benefits.

Для цитирования: Tan Min Choon, Vignarajah Aravinthan, Teo Yong Shen, Vigneswaramoorthy Nishanthi, DeSimone Christopher V, Deshmukh Abhishek J, Sorajja Dan, Lee Justin Z. Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis.. JACC. Clinical electrophysiology. 2025. DOI: 10.1016/j.jacep.2025.09.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.